With seven approved AAV therapies and over 200 ongoing clinical trials, the potential of AAV-based gene therapies is exciting — but success requires overcoming significant hurdles.

Discover how advanced AAV capsid engineering techniques have the potential to enhance gene therapy development in our white paper. Find out how tailored AAV capsids can help to improve tissue tropism, explore new targets, minimize off-target effects, and potentially reduce immunogenicity.

You will learn about:

• Key challenges in AAV-based therapies and strategies to overcome them
• Evolutionary approaches to AAV optimization
• A comparison of these approaches
• Typical workflow from library design to biodistribution studies

Download our white paper to learn how Revvity's expertise across the entire AAV development pipeline can help to accelerate your gene therapy's journey from concept to clinic.

A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.